Skip to main content Accessibility help

Some Factors to Consider when Using the Results of Economic Evaluation Studies at the Population Level

  • Reiner M. Leidl (a1)


The cost-effectiveness of a medical intervention at the population level may deviate from that reported for evaluations at the patient level. It is important for researchers and decision makers to know about the relevance of externalities, phasing-in effects, treatment effectiveness in the community, capacity issues, and different time perspectives in the evaluation of an intervention.



Hide All
1.Anderson, R. M., Gupta, S., & May, R. M.Potential of community-wide chemotherapy or immunotherapy to control the spread of HIV 1. Nature, 1991, 350, 356–59.
2.Backhouse, M. E., Backhouse, R. J., & Edey, S. A.Economic evaluation bibliography. Health Economics, 1992, 1 (suppl.), 1236.
3.Banta, H. D., & Bos, M.The relation between quantity and quality with coronary artery bypass graft (CABG) surgery. Health Policy, 1991, 18, 110.
4.Banta, H. D., Vondeling, H., de Wit, A., & Haan, G.Economic appraisal of laser applications in medicine. Lasers in Medical Science, 1990, 5, 253–69.
5.Birch, S., & Gafni, A.Cost effectiveness/utility analyses. Do current decision rules lead us to where we want to be? Journal of Health Economics, 1992, 11, 279–96.
6.Culyer, A. J.The nature of the commodity ‘health care’ and its efficient allocation. Oxford Economic Papers, 1971, 23, 189211.
7.Detsky, A. S.Guidelines for economic analysis of pharmaceutical products: A draft document of Ontario and Canada. Pharmaco Economics, 1993, 2, 354–61.
8.Droitcour, J., Silberman, G., & Chelmisky, E.Cross-design synthesis. International journal of Technology Assessment in Health Care, 1993, 9, 440–49.
9.Drummond, M., Brandt, A., Luce, B., & Rovira, J.Standardizing methodologies for economic evaluation in health care: Practice, problems and potential. International Journal of Technology Assessment in Health Care, 1993, 9, 2635.
10.Drummond, M. F., & Davies, L.Economic analysis alongside clinical trials: Revisiting the methodological issues. International Journal of Technology Assessment in Health Care, 1991, 7, 561–73.
11.Gafni, A., & Birch, S.Guidelines for the adoption of new technologies: A prescription for uncontrolled growth in expenditures and how to avoid the problem. Canadian Medical Association Journal, 1993, 148, 913–29.
12.Garber, A. M.Competing risks and the cost-effectiveness of health interventions (1989 Annual Meeting Program and Abstracts). Medical Decision Making, 1989, 9, 319.
13.Gerard, K., & Mooney, G.QALY league tables: Handle with care. Health Economics, 1993, 2, 5964.
14.Haan, G.Effects and costs of in-vitro fertilization: Again, let’s be honest. International Journal of Technology Assessment in Health Care, 1991, 7, 585–93.
15.Hannan, E. L., O’Donnell, J. F., Kilburn, H., et al. Investigation of the relationship between volume and mortality for surgical procedures performed in New York State hospitals. Journal of the American Medical Association, 1989, 262, 503–10.
16.Henry, D.Economic analysis as an aid to subsidisation decisions: The development of Australian guidelines for Pharmaceuticals. Pharmaco Economics, 1992, 1, 5467.
17.Javitt, J. C., Canner, J. K., Frank, R., et al. Detecting and treating retinopathy in patients with type I diabetes mellitus. A health policy model. Ophthalmology, 1990, 97, 483–95.
18.Javitt, J. C., Lloyd, P. A., Bassi, L. J., et al. Detecting and treating retinopathy in patients with type I diabetes mellitus. Savings associated with improved implementation of current guidelines. Ophthalmology, 1991, 98, 1565–74.
19.Labelle, R. J., & Hurley, J. E.Implications of basing health-care resource allocations on cost-utility analysis in the presence of externalities. Journal of Health Economics, 1992, 11, 259–77.
20.Laupacis, A., Feeney, D., Detsky, A., et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Canadian Medical Association Journal, 1992, 146, 473–81.
21.Leidl, R.A survey of the economic evaluation of early drug intervention in HIV infection. Working towards a population-based approach. In Kaplan, E. H. & Brandeau, M. L. (eds.), Modeling the AIDS epidemic: planning, policy, and prediction. New York: Raven Press, 1994, 253–71.
22.Morgenstern, W., Chigan, E., Prokhorskas, R., et al. (eds.). Models of noncommunicable diseases. Health status and health service requirements. Berlin: Springer, 1992.
23.Paltiel, A. D., & Kaplan, E. H.Modeling Zidovudine therapy: A cost-effectiveness analysis. Journal of the Acquired Immune Deficiency Syndrome, 1991, 4, 795804.
24.Postma, M. J., Leidl, R., Downs, A. M., et al. Economic impact of the AIDS epidemic in EC countries: Towards multinational scenarios on hospital care and costs AIDS, 1993, 7, 541–53.
25.Rosendal, H., Vondeling, H., & Banta, H. D.Diffusion of medical lasers in the Netherlands. In Spinelli, P., Dal Fante, M., & Marchesini, R. (eds.), Photodynamic therapy and biomedical lasers. Amsterdam: Elsevier, 1992, 122–26.
26.Schulman, K. A., Lynn, L. A., Glick, H. A., & Eisenberg, J. M.Cost-effectiveness of low-dose Zidovudine therapy for asymptomatic patients with human immunodeficiency virus (HIV) infection. Annals of Internal Medicine, 1991, 14, 798802.
27.Tugwell, P., Bennett, K. J., Sackett, D. L., & Haynes, R. B.The measurement iterative loop: A framework for the critical appraisal of need, benefits and costs of health interventions. Journal of Chronic Diseases, 1985, 38, 339–51.
28.van Hout, B., Bonsel, G., Habbema, D., & van der Maas, P.Heart transplantation in the Netherlands; Cost, effects and scenarios. Journal of Health Economics, 1993, 12, 7393.
29.Vrieze, O. J., Kuipers, J., & Boas, G.Scenario analysis in public health and competing risks. Statistica Applicata, 1990, 2, 371–93.
30.Weinstein, M. C., Coxon, P. G., Williams, L. W., et al. Forecasting coronary heart disease incidence, mortality, and cost: The coronary heart disease policy model. American Journal of Public Health, 1987, 77, 1417–26.
31.Yashin, A. I., Manton, K. G., & Vaupel, J. W.Mortality and aging in a heterogeneous population: A stochastic process model with observed and unobserved variables. Theoretical Population Biology, 1985, 27, 154–75.

Related content

Powered by UNSILO

Some Factors to Consider when Using the Results of Economic Evaluation Studies at the Population Level

  • Reiner M. Leidl (a1)


Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.